Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Regen-Cov
|
| gptkbp:activities |
neutralizes SARS-Co V-2 virus
|
| gptkbp:appointed_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:can_be_used_with |
gptkb:bamlanivimab
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:developed_by |
gptkb:Eli_Lilly_and_Company
|
| https://www.w3.org/2000/01/rdf-schema#label |
imdevimab
|
| gptkbp:indication |
mild to moderate COVID-19 in high-risk patients
|
| gptkbp:ingredients |
C6484 H10000 N1716 O2000 S44
|
| gptkbp:is_used_for |
treatment of COVID-19
|
| gptkbp:manager |
intravenous
|
| gptkbp:marketed_as |
the brand name Bamlanivimab/ Etesevimab
|
| gptkbp:side_effect |
fatigue
headache nausea diarrhea infusion-related reactions |
| gptkbp:targets |
Spike protein of SARS-Co V-2
|